Sorry @Dexter_Scott , I’m a bit slow today. I breezed through the paper you attached. The author wrote “ Chelation therapy with disodium EDTA has been in use for the treatment of atherosclerotic disease for 58 years. During most of that period, many medical organizations have declared it to be unsafe and relegated the treatment to the realm of alternative medicine. ” but then show results which looked interesting to me.
So are you saying that doctors find it quackery but it still has a meaningful impact? Or are you saying doctors find it quackery because it is quackery?
Also, is Nattokinase a chelating agent? Or is it some to Ing else? It seems from the attached paper that it may be more complex. (I can’t speak for the quality of the paper, but I was simply looking to answer the question of whether Nattokinase was a chelating agent)
https://www.sciencedirect.com/science/article/pii/S1674638423000564
3. Pharmacological actions of natto
3.1. Thrombolytic effects
In 1987, an alkaline protease was extracted and isolated from natto for the first time, which was named as nattokinase (NK) and its molecular formula is C20H23BCl2N2O9 (Sumi, Hamada, Tsushima, Mihara, & Muraki, 1987). It was confirmed that NK has a strong effect of thrombus dissolution through the dog thrombosis model. Current researches showed that the thrombolytic mechanism of NK mainly includes five aspects (Chen, Sha, Ren, Xi, & Wang, 2003; Weng, Yao, Sparks, & Wang, 2017): (1) Dissolving thrombus by directly dissolving fibrin (skeleton structures of thrombus). Studies have shown that NK can directly act on the enzyme cleavage sites of cross-linked fibrin thrombus len-tyr and Ser-hrs to hydrolyze long-chain skeleton fibrin into soluble small molecules, so as to directly dissolve thrombus. (2) Inhibition of platelet aggregation. NK can reduce the elevated levels of thromboxane (B2) and prostaglandin E2 (PGE2) in the plasma of the model group, and increase the level of 6-keto-prostaglandin F1α (6-K-PGF1α) to prevent platelet aggregation and inhibit the formation of thrombosis (Yan, Feng, Xu, & Wu, 2021). Furthermore, preincubating NK and platelet for 10 min in buffer solution could inhibit the increase of Ca2+ induced by thrombin to repress platelet aggregation (Ji et al., 2014). (3) NK stimulates vascular endothelial cells to produce tissue-type plasminogen activator (t-PA) and inhibit the production of plasminogen activator inhibitor-1 (PAI-1) of endothelial cells (Ji et al., 2014, Yatagai et al., 2007). As shown in Fig. 1, t-PA activates fibrinogen in vivo to form fibrinolytic enzymes, which dissolve fibrin emboli. T-PA is about 6–7 ng/mL in a normal body, while it is detected to be more than 10 ng/mL 4 h after oral NK. Therefore, it can be inferred that NK can play a thrombolytic role by stimulating the body to produce T-PA and increasing fibrinolytic activity. In addition, a study has shown that the dose dependence of PAI-1 content decreased with the increase of NK concentration in a certain range of concentration, which indicated that to a certain degree NK might play antithrombotic role through reducing the PAI-1 secretion level of endothelial cells (Shah & Minocheherhomji, 2022). (4) Catalyzing the conversion of prourokinase to urokinase. It has been suggested that NK can also activate prourokinase to produce urokinase, another fibrinogen activator, to accelerate thrombolysis in vivo(Weng, Yao, Sparks, & Wang, 2017). (5) In addition, the multifunctional cationic peptides from natto extracts exhibit angiogenic activities in tube formation assays, which indicated that the bioactive peptides potentially contribute to antithrombotic effects (Taniguchi et al., 2019).